Cover Image
市場調查報告書

LG Life Sciences, Ltd. - 產品平台分析

LG Life Science LTD. - Product Pipeline Review - 2016

出版商 Global Markets Direct 商品編碼 224575
出版日期 內容資訊 英文 71 Pages
訂單完成後即時交付
價格
Back to Top
LG Life Sciences, Ltd. - 產品平台分析 LG Life Science LTD. - Product Pipeline Review - 2016
出版日期: 2016年09月30日 內容資訊: 英文 71 Pages
簡介

LG Life Sciences, Ltd.是總公司設立於韓國的製藥企業,正在開發·商品化疫苗,感染疾病治療藥,玻尿酸等產品,並提供化學產品,家畜用醫藥品,美容醫藥品,內分泌系用醫藥品,不孕治療藥等。

本報告提供LG Life Sciences, Ltd. 的治療藥開發平台現狀及各開發階段比較分析,提供您藥物標的,作用機制,給藥途徑,各分子類型的治療藥評估,最新的企業新聞和發表,後期階段及中止的計劃相關等資訊。

目錄

LG Life Sciences, Ltd. 的基本資料

  • LG Life Sciences, Ltd. 概要
  • 主要資訊
  • 企業資料

LG Life Sciences, Ltd. :R&D概要

  • 主要的治療範圍

LG Life Sciences, Ltd. :開發平台評估

  • 各開發階段的開發中產品
  • 單劑產品
  • 聯合治療模式
  • 合作夥伴產品
    • 合作夥伴產品/聯合治療模式
  • 轉出授權產品
    • 轉出授權產品/聯合治療模式

LG Life Sciences, Ltd. :開發中產品概況

  • 後期階段產品開發中產品
    • 登記申請前的產品/聯合治療模式
    • 第Ⅲ階段的產品/聯合治療模式
  • 臨床階段的開發中產品
    • 第Ⅱ階段的產品/聯合治療模式
    • 第Ⅰ階段的產品/聯合治療模式
  • 初期階段的開發中產品
    • 前臨床階段的產品/聯合治療模式
    • 藥物研發階段的產品/聯合治療模式
  • 開發階段不明的開發中產品
    • 開發階段不明的產品/聯合治療模式

LG Life Sciences, Ltd. :藥物簡介

  • somatropin SR
  • (gemigliptin + rosuvastatin calcium)
  • diphtheria + tetanus + pertussis (whole-cell) + hepatitis B + haemophilus influenzae serotype B vaccine
  • etanercept biosimilar
  • somatropin (recombinant)
  • (lercanidipine hydrochloride + valsartan)
  • interferon alfa-2a SR
  • LC-280126
  • LD-02GIFRO
  • nivocasan
  • (gemigliptin + sulfonylureas)
  • adalimumab biosimilar
  • LC-231306
  • LC-350189
  • infliximab biosimilar
  • LC-280391
  • NecX
  • Small Molecules For Obesity
  • exenatide SR
  • LC-34AD3
  • LC-54AID3
  • rituximab biosimilar
  • Small Molecule To inhibit PAR-1 for Atherothrombosis
  • Monoclonal Antibody to Inhibit VEGF for Cancer

LG Life Sciences, Ltd. :開發平台分析

  • 標的別
  • 各給藥途徑
  • 各分子類型
  • 各作用機制

LG Life Sciences, Ltd. :最新的開發平台資訊

LG Life Sciences, Ltd. :開發被休止的計劃

LG Life Sciences, Ltd. :總公司和子公司的所在地

  • 總公司
  • 分公司及子公司

附錄

圖表一覽

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: GMDHC08143CDB

Summary

Global Markets Direct's, 'LG Life Science LTD. - Product Pipeline Review - 2016', provides an overview of the LG Life Science LTD.'s pharmaceutical research and development focus.

The report provides comprehensive information on the therapeutics under development by LG Life Science LTD., complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and the dormant and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

  • The report provides a snapshot of the pipeline therapeutic landscape of LG Life Science LTD.
  • The report provides overview of LG Life Science LTD. including its business description, key facts, and locations and subsidiaries
  • The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
  • The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • The report assesses LG Life Science LTD.'s pipeline therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type
  • The report features LG Life Science LTD.'s out-licensed and partnered product portfolio and summarizes its dormant and discontinued projects

Reasons to buy

  • Evaluate LG Life Science LTD.'s strategic position with total access to detailed information on its product pipeline
  • Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Identify and understand important and diverse types of therapeutics under development for LG Life Science LTD.
  • Identify potential new clients or partners in the target demographic
  • Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics
  • Devise corrective measures for pipeline projects by understanding LG Life Science LTD.'s pipeline depth and focus of pipeline therapeutics
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Table of Contents

  • Table of Contents
    • List of Tables
    • List of Figures
  • LG Life Science LTD. Snapshot
    • LG Life Science LTD. Overview
    • Key Facts
  • LG Life Science LTD. - Research and Development Overview
    • Key Therapeutic Areas
  • LG Life Science LTD. - Pipeline Review
    • Pipeline Products by Stage of Development
    • Pipeline Products - Monotherapy
    • Pipeline Products - Combination Treatment Modalities
    • Pipeline Products - Partnered Products
      • Partnered Products/Combination Treatment Modalities
    • Pipeline Products - Out-Licensed Products
      • Out-Licensed Products/Combination Treatment Modalities
  • LG Life Science LTD. - Pipeline Products Glance
    • LG Life Science LTD. - Late Stage Pipeline Products
      • Pre-Registration Products/Combination Treatment Modalities
      • Phase III Products/Combination Treatment Modalities
    • LG Life Science LTD. - Clinical Stage Pipeline Products
      • Phase II Products/Combination Treatment Modalities
      • Phase I Products/Combination Treatment Modalities
    • LG Life Science LTD. - Early Stage Pipeline Products
      • Preclinical Products/Combination Treatment Modalities
      • Discovery Products/Combination Treatment Modalities
    • LG Life Science LTD. - Unknown Stage Pipeline Products
      • Unknown Products/Combination Treatment Modalities
  • LG Life Science LTD. - Drug Profiles
    • (gemigliptin + glimepiride) - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • (gemigliptin + metformin hydrochloride) - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • (gemigliptin + rosuvastatin calcium) - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • (lercanidipine hydrochloride + valsartan) - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • adalimumab biosimilar - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • etanercept biosimilar - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Eupenta - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • exenatide SR - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • infliximab biosimilar - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • interferon alfa-2a SR - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • LBDE - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • LBVC - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • LBVD - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • LBVE-013 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • LBVE-014 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • LC-231306 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • LC-280126 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • LC-280391 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • LC-34AD3 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • LC-350189 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • LC-541239 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • LC-65AOD3 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • LD-02GIFRO - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Monoclonal Antibody to Inhibit VEGF for Cancer - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • NecX - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • nivocasan - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • rituximab biosimilar - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Small Molecule to Inhibit PAR-1 for Atherothrombosis - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Small Molecules for Obesity - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Small Molecules to Inhibit 20S Proteasome for Multiple Myeloma and Solid Tumor - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • somatropin - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • somatropin SR - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
  • LG Life Science LTD. - Pipeline Analysis
    • LG Life Science LTD. - Pipeline Products by Target
    • LG Life Science LTD. - Pipeline Products by Route of Administration
    • LG Life Science LTD. - Pipeline Products by Molecule Type
    • LG Life Science LTD. - Pipeline Products by Mechanism of Action
  • LG Life Science LTD. - Dormant Projects
  • LG Life Science LTD. - Locations And Subsidiaries
    • Head Office
    • Other Locations & Subsidiaries
  • Appendix
    • Methodology
    • Coverage
    • Secondary Research
    • Primary Research
    • Expert Panel Validation
    • Contact Us
    • Disclaimer

List of Tables

  • LG Life Science LTD., Key Facts
  • LG Life Science LTD. - Pipeline by Indication, 2016
  • LG Life Science LTD. - Pipeline by Stage of Development, 2016
  • LG Life Science LTD. - Monotherapy Products in Pipeline, 2016
  • LG Life Science LTD. - Combination Treatment Modalities in Pipeline, 2016
  • LG Life Science LTD. - Partnered Products in Pipeline, 2016
  • LG Life Science LTD. - Partnered Products/ Combination Treatment Modalities, 2016
  • LG Life Science LTD. - Out-Licensed Products in Pipeline, 2016
  • LG Life Science LTD. - Out-Licensed Products/ Combination Treatment Modalities, 2016
  • LG Life Science LTD. - Pre-Registration, 2016
  • LG Life Science LTD. - Phase III, 2016
  • LG Life Science LTD. - Phase II, 2016
  • LG Life Science LTD. - Phase I, 2016
  • LG Life Science LTD. - Preclinical, 2016
  • LG Life Science LTD. - Discovery, 2016
  • LG Life Science LTD. - Unknown, 2016
  • LG Life Science LTD. - Pipeline by Target, 2016
  • LG Life Science LTD. - Pipeline by Route of Administration, 2016
  • LG Life Science LTD. - Pipeline by Molecule Type, 2016
  • LG Life Science LTD. - Pipeline Products by Mechanism of Action, 2016
  • LG Life Science LTD. - Dormant Developmental Projects,2016
  • LG Life Science LTD., Other Locations
  • LG Life Science LTD., Subsidiaries

List of Figures

  • LG Life Science LTD. - Pipeline by Top 10 Indication, 2016
  • LG Life Science LTD. - Pipeline by Stage of Development, 2016
  • LG Life Science LTD. - Monotherapy Products in Pipeline, 2016
  • LG Life Science LTD. - Combination Treatment Modalities in Pipeline, 2016
  • LG Life Science LTD. - Out-Licensed Products in Pipeline, 2016
  • LG Life Science LTD. - Pipeline by Top 10 Target, 2016
  • LG Life Science LTD. - Pipeline by Route of Administration, 2016
  • LG Life Science LTD. - Pipeline by Molecule Type, 2016
  • LG Life Science LTD. - Pipeline Products by Top 10 Mechanism of Action, 2016
Back to Top